Benoît You
YOU?
Author Swipe
View article: Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
MGMC and GIScar scores among concordant and discordant HRD classification on the clinical collection (n = 469)
View article: Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
PAOLA-1 Investigators
View article: Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Histologic type of tumors used in this study (n = 719)
View article: Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Additional information regarding the GIScar training (N = 250 tumors).
View article: Supplementary Figure S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Kaplan–Meier estimates of PFS stratified on treatment arm (n = 469).
View article: Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Kaplan–Meier estimates of PFS stratified on Giscar HRD status among inconclusive status of MGMC (n = 43).
View article: Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer Open
PURPOSE In patients with ovarian cancer undergoing neoadjuvant chemotherapy (NACT) with the goal of achieving complete interval cytoreductive surgery (ICS), tools are needed to accurately assess NACT efficacy and predict the feasibility of…
View article: 1307 ICT01, a γ9δ2 T-cell-activating mAb, in combination with pembrolizumab elicits deep and durable responses in second-line patients with primary refractory melanoma: Results from EVICTION study
1307 ICT01, a γ9δ2 T-cell-activating mAb, in combination with pembrolizumab elicits deep and durable responses in second-line patients with primary refractory melanoma: Results from EVICTION study Open
View article: KIAA1429 in non-small cell lung cancer: bridging m6A epigenetics to therapeutic innovation
KIAA1429 in non-small cell lung cancer: bridging m6A epigenetics to therapeutic innovation Open
As a pivotal component of the m6A methyltransferase complex, KIAA1429 plays a critical regulatory role in the pathogenesis of non-small cell lung cancer (NSCLC), driving tumorigenesis, metastasis, and therapeutic resistance through epigene…
View article: Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis Open
The pragmatic KELIM score is an independent prognostic factor in patients with a non-mucinous stage I to II ovarian cancer optimally resected and treated with adjuvant chemotherapy. KELIM may help identify the patients at higher risk of re…
View article: A randomized, phase III study of sacituzumab govitecan versus treatment of the physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2) Open
NCT06486441; GOG-3104; ENGOT-en26; APGOT-EN2.
View article: Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Open
View article: Comparative impact of social isolation on mortality in adults aged 40 years and above with versus without metabolic syndrome: evidence from two large cohorts in the U.S. and U.K.
Comparative impact of social isolation on mortality in adults aged 40 years and above with versus without metabolic syndrome: evidence from two large cohorts in the U.S. and U.K. Open
View article: Results of a National French Survey on use of KELIM model for management of patients with advanced stage epithelial ovarian cancer (SFOG Campus)
Results of a National French Survey on use of KELIM model for management of patients with advanced stage epithelial ovarian cancer (SFOG Campus) Open
The KELIM score predictive value for chemosensitivity, is acknowledged, especially for bevacizumab indications. However, its adoption into routine practice is dependent on the level of familiarity of practitioners. The findings suggest tha…
View article: SPDL1 overexpression was associated with poor prognosis and immune status in HCC through in vitro experiment and bioinformatics analysis
SPDL1 overexpression was associated with poor prognosis and immune status in HCC through in vitro experiment and bioinformatics analysis Open
Overexpression of SPDL1 is associated with poor prognosis and the immune microenvironment in HCC. Inhibition of SPDL1 expression can suppress tumor growth and metastasis, suggesting that SPDL1 may serve as a potential therapeutic target fo…
View article: Associations of socioeconomic status and health lifestyles with chronic obstructive pulmonary disease: two nationwide population-based studies
Associations of socioeconomic status and health lifestyles with chronic obstructive pulmonary disease: two nationwide population-based studies Open
Low SES significantly contributes to COPD risk, but a healthy lifestyle mediating this association. Promoting healthy lifestyle choices and addressing socioeconomic disparities are essential public health strategies for COPD prevention. Ad…
View article: Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study Open
Background hPG 80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO cent…
View article: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial Open
View article: Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial Open
The poor prognostic OC patient subgroup, may have an extension of PFS from treatment intensification with atezolizumab added to frontline chemotherapy-bevacizumab regimen. This hypothesis-generating outcome warrants further understanding o…
View article: Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin Open
These results support that patients experiencing any-grade cutaneous toxicity (skin rash) had a prolonged PFS. With the recent expansion of combined treatment using EV plus pembrolizumab in first-line in mUC patients, cutaneous toxicities …
View article: Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial Open
View article: Hpv Circulating Tumor DNA to Monitor Response to Pembrolizumab and Vorinostat Combination in Patients with Advanced Hpv-Related Squamous Cell Carcinomas
Hpv Circulating Tumor DNA to Monitor Response to Pembrolizumab and Vorinostat Combination in Patients with Advanced Hpv-Related Squamous Cell Carcinomas Open
View article: Benefit from the Immune Checkpoint Inhibitor Atezolizumab Addition in Poor Prognostic Ovarian Cancer Patients : Imagyn050 Trial
Benefit from the Immune Checkpoint Inhibitor Atezolizumab Addition in Poor Prognostic Ovarian Cancer Patients : Imagyn050 Trial Open
View article: Utility of the CA125 KELIM in for Predicting the Benefit of from HIPECin Patients with Advanced Ovarian Cancer: Pooled Analysis of Individual Data from KGOG3042 and KOV-HIPEC-01
Utility of the CA125 KELIM in for Predicting the Benefit of from HIPECin Patients with Advanced Ovarian Cancer: Pooled Analysis of Individual Data from KGOG3042 and KOV-HIPEC-01 Open
View article: Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib Open
Background The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors represented a paradigm shift in the treatment of ovarian cancer. Genomic data from patients with high-grade ovarian cancer in six phase II/III trials involving th…
View article: Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer Open
Background High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm’s chemotherapy response…
View article: 692 ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with refractory melanoma: interim results from study EVICTION
692 ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with refractory melanoma: interim results from study EVICTION Open
View article: 641 ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with urothelial cell carcinoma: interim results from study EVICTION
641 ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with urothelial cell carcinoma: interim results from study EVICTION Open
View article: Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer Open
View article: FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia Open
Our work demonstrates that antibody-dependent cell-mediated cytotoxicity contributes to the therapeutic effect of avelumab in gestational trophoblastic neoplasia and that the individual patient response is impacted by the FcγR3A polymorphi…